Biopterin as a stable metabolite is produced by oxidation of 5, 6, 7, ). It is known that many diseases may cause changes in BH 4 concentration and/or dihydropteridine reductase (DHPR) enzyme activity. There is only a limited number of studies correlating DHPR activity in malignancies. The main goal of the present study was to evaluate alterations in the DHPR activity and biopterin levels in patients with breast and thyroid cancers. The breast cancer patients (n=24) were compared to patients with benign breast diseases (n=19) and controls (n=30). In addition; the patients with thyroid cancer (n=17) were compared to patients with benign thyroid diseases (n=42) and the control group. We did not observe any significant difference between the benign disorders and the malignancies. Biopterin concentrations in patients with benign and malign thyroid and breast diseases were lower than the controls (all p <0.05). DHPR activities in thyroid diseases were significantly higher than the controls while insignificant decreases in DHPR activities in breast patients were detected. Our results suggested significant alterations in unconjugated pteridine pathway in thyroid and breast disorders.
Introduction

5,6,7,8-Tetrahydrobiopterin (BH
) is an endogenously synthesized cofactor, required for various enzyme activities and for some less well-defined functions on the cellular level (1) . BH 4 is best recognized as the essential, non-protein cofactor for the aromatic amino acid monooxygenases, that rate limiting enzymes in phenylalanine, tyrosine, and tryptophan catabolism and in biosynthesis of the neurotransmitters dopamine and serotonin (2) . Every cell or tissue of higher organisms possibly contains BH 4 , which additionally appears to be involved in other metabolic and cellular functions (2) . BH 4 is an essential cofactor for phenylalanine hydroxylases, glyceryl-ether monooxygenase, and three main nitric oxide synthase isoenzymes (3) . Thus far, nitric oxide synthase is the only enzyme where biopterin radical formation is clearly linked to its catalytic properties (4) .
The chronic immune system activation appears to be a major cause of the loss of antioxidants and the development of oxidative stress. Subnormal concentrations of antioxidants, like vitamin C and E, have been observed in diseases associated with immune activation and inflammation, and may also impair availability of BH 4 in patients with malignancy (5, 6) . These clinical conditions are known to be linked with inflammation and immune activation and with increased concentrations of immune activation markers such as serum soluble 75 kDa tumor necrosis factor-α (sTNF-R75) and neopterin (7, 8) . On the other hand, it has been shown that BH 4 enhances the proliferative activity of hemopoietic and leukemic cells (2) . Regeneration of BH 4 from its oxidized forms is particularly important in biological system (4). The enzymes, pterin-4a-carbinolamine dehydratase and dihydropteridine reductase (DHPR) are responsible for the regeneration of BH 4 (7) (8) (9) . As shown in Figure 1 , the quinonoid form of dihydrobiopterin is mainly reduced by DHPR (4) . It has been recognized that many diseases and xenobiotics including drugs may cause a change in BH 4 concentration and/or DHPR activity (10) (11) (12) (13) (14) (15) .
Tetrahydropterins such as BH 4 are labile in solution and react with oxygen, superoxide, hydrogen peroxide, and peroxynitrite because this molecule has a core structure of two or three heterocyclic six-membered rings (4) . This property has been suggested to act as a self-protection in order to protect cells against oxidative damage (4, 7, 8) . It is also known that the role of pteridine derivatives in oxidative stress may differ according to the conditions (Figure 1 ) (16) (17) (18) (19) (20) (21) . For instance, neopterin derivatives may directly interfere with the intracellular redox balance as a potential function of neopterin and 7,8-dihydroneopterin in oxygen radical mediated process (20, 21) . The role of inflammation is a debated subject in the area of cancer research and furthermore the role of inflammatory markers in the follow up of malignancy and the follow up of response to therapy is continuously investigated (22) . In our previous studies we have focused on neopterin as a biomarker part in the pterin pathway in both of patients with thyroid and breast disorders (23, 24) . Still there is only a limited number of studies on changes in BH 4 pathway and/or DHPR activity in cancer patients (25) (26) (27) (28) (29) (30) (31) (32) (33) . Therefore, in the present study we evaluated the alteration in biopterin excretion and DHPR activity which would reflect impairment of BH 4 maintenance in patients with breast and thyroid disorders.
Materials and Methods
Subjects
Total one-hundred-two patients were included in the study and the demographics of the subjects are presented in Table 1 . Forty-three of them were operated The benign tumor group consisted of fibroadenoma and fibrocystic disease patients. The preoperative diagnosis of all breast cancer patients were confirmed by core biopsy and recurrent cases were excluded from the study. The exclusion criteria of the study were; obscure perioperative diagnosis, history of chemotherapy or radiotherapy, the patients with familial pattern of breast diseases, the patients who had a history of breast or other organ malignancies and presence of active infection at the time of sample collection. Fiftynine of the patients were operated for various thyroid disorders. Seventeen of the thyroid patients were papillary thyroid cancer while the others were benign thyroid disorders (including thyroiditis and multinodular goiter). Preoperative malignancy was diagnosed by fine needle aspiration biopsy. The excluding criteria were; preoperative indetermined diagnosis of malignancy, history of chemotherapy or who are currently receiving antithyroid therapy, history of irradiation to the neck and history of prior thyroid surgery. All the patients were euthyroid at the time of operation. The control group consisted of thirty healthy subjects who work in the Faculty and were systemically healthy and had not received any medication during this period. The principles of the Ethical Committee according to the Helsinki Declaration were followed during the study.
Measurements of biopterin
Urine samples were collected early in the morning before the operation and kept from direct light. All samples were stored at -20°C until the assayed. Biopterin concentrations in each urine sample were analyzed by high performance liquid chromatography (HPLC, HP Agilent 1100, Vienna, Austria) without any oxidation step during sample preparation. A column (25 cm X 4.6 mm) containing octadodecyl silica gel C 18 (5 µm particle size; Hichrom), protected with a 4-cm guard column filled with the same material was used. Biopterin was isocratically eluted at a flow rate of 1 mL/min with 15 mM potassium dihydrogen phosphate buffer containing 2.5% methanol (v/v), pH 7.0 and quantified using a fluorescence detector (λex: 353 nm, λem: 438 nm). Creatinine concentrations were determined simultaneously by using an ultraviolet detector (HP Agilent 1100) at the wavelength of 235 nm. The biopterin levels were expressed as micromoles of biopterin per mole of creatinine.
DHPR measurements
Peripheral venous blood samples from the subjects were drawn and dropped on a filter paper. DHPR enzyme assay was performed on dry blood spots. After measuring the diameter of each blood spot, it was cut and extracted with 0.15 M cold KCl solution at 0 -4 °C. This elute was used in the assay of DHPR enzyme activity. Enzyme activity was measured spectrophotometrically at 550 nm wavelength (Shimadzu UV160, Japan) by following the BH 4 -dependent reduction of ferricytochrome C in the presence of NADH (14) . The assay tube contained Tris-HCl buffer, pH 7.6, ferricytochrome C in Tris HCl containing KCl, pH 7.6, NADH in KOH, 6-methyl-tetrahydropteridine (Sigma, USA) in 0.01 M HCl and the enzyme extract, in a final volume of 2 ml. To correct for pterin and enzyme-independent reduction of ferricytochrome C, appropriate blanks were used. The enzyme activity was expressed as nanomoles of cytochrome C reduced per minute relative to the 6 mm diameter of blood spots.
Statistical analysis
All of the results are expressed as the mean ± standard error of mean (SEM). Because not all data sets showed normal distribution, non-parametric methods were used for their statistical analyses. The differences among the groups were evaluated with Kruskal-Wallis analysis of variance, and comparisons between two independent groups were made with the MannWhitney U-test. The correlations of the parameters were detected by Spearman non-parametric correlation test. Furthermore the results were confirmed with a multivariate regression model. P <0.05 was considered statistically significant.
Results
The mean biopterin excretion was found as 93.9 ± 7.12 µmol/mol creatinine in the controls while the mean results were 32.8 ± 4.32 and 31.4 ± 5.38 µmol/mol creatinine in benign and malign breast tumors, respectively. As shown in Figure 2 , biopterin concentrations in both benign and malign breast patients were statistically lower than in controls (both p <0.001). However, there was no significant difference between benign and malign breast disorders groups. The biopterin concentrations in benign and malign thyroid disorders were determined as 64.2 ± 6.26 and 82.6 ± 15.5 µmol/mol creatinine, respectively. There was no difference in biopterin concentrations between benign and malign thyroid groups (not significant), while there were significant differences between the controls and benign cases (p <0.001) or malign thyroid patients (p = 0.025).
The results of measurements of DHPR activity in the study groups were given in Figure 3 . There were no significant differences in DHPR activities among the Figure 3 .Box plots of blood dihydropteridine reductase (DHPR) activities of the patients groups (shown are medians = horizontal lines, interquartile ranges = boxes, and ranges = bars). MT, malign thyroid (n = 17); BT, benign thyroid (n = 42); MB, malign breast (n = 24); BB, benign breast diseases (n = 19), and C, control group (n = 30). †p <0.05 vs. control group † † breast disorders groups and the control group (both not significant). Conversely, the mean values of DHPR activity in both of the benign and malign thyroid groups were significantly higher than the control results (both p <0.05). However, the difference between benign and malign thyroid patients was not significant (not significant).
There were no correlations between the mean biopterin concentrations and DHPR activities in the study groups (all not significant).
The effects of age and gender on biopterin levels and the enzyme activities were checked in control healthy subjects. There were neither associations between age and the measured biopterin concentrations nor the DHPR activities (all not significant). Furthermore, gender did not affect the results either (all not significant).
Discussion
For the last 40 years, the evaluation of pteridines has been focused on obtaining knowledge about the unconjugated pteridine pathway (34) . Due to the instability of BH 4 , the main metabolites neopterin and biopterin are preferred to gain further information on the pathway. A number of publications has documented the anomalies in unconjugated pteridines metabolism in patients suffering from malignant diseases, in which there was a characteristically elevated urinary excretion of neopterin, which is produced in human monocytes/macrophages at the expense of BH 4 (15, (22) (23) (24) (35) (36) (37) . The studies have potentiated the role of neopterin as the biomarker of immune system stimulation. Therefore in our previous studies we have demonstrated the correlation of serum and urinary neopterin concentrations with the malignant breast and thyroid disorders (23, 24, 37) . Furthermore, we have also emphasized the correlation between neopterin concentrations and the grade of the tumors (23, 24) .
DHPR converts quinonoid dihydrobiopterin to BH 4 in a NADH-mediated reaction (38) . The measurement of pterins in different biological fluids is the most common method for the screening and differential diagnosis of inborn errors of BH 4 metabolism (39). In addition, biopterin accumulates upon oxidation of BH 4 and is excreted by urine (34) . Therefore we preferred to detect the biopterin in the urine samples of the patients in our study.
Thyroid is an oxidatively active organ and the majority of thyroid tumors represent well differentiated functional tumors (24) . Thyrocytes produce constantly moderate amounts of reactive oxygen species (ROS), which are physiologically required for thyroid hormone synthesis. To maintain cell integrity, several protective systems against ROS are active in thyrocytes. Increased oxidative stress is not necessarily lethal for goitrous cells but is associated with large cellular destruction and inflammation in iodine-induced thyroid involution (40) . Our results pointed out decreased urinary biopterin in both of the thyroid and breast disorders in comparison with the control subjects. This situation is not a surprising outcome since it might originate from an increased DHPR activity. In the present study we have found that the urinary biopterin levels in malignant tumors of thyroid were higher when compared to benign counterparts which are suggestive of a better antioxidant protection in patients with benign diseases. The increase in DHPR activity may be an adaptive process to enhanced oxidative stress which is not well compensated by other antioxidant mechanisms.
Dhondt et al. (27) focused on a study in order to evaluate DHPR activity in breast cancer patients and they reported that large variations in breast malignancy. Furthermore, they pointed out a significant correlation between DHPR activity and hormonal dependence, as measured by cytosolic estrogen receptor sites. In another study performed by Sanchez-Urretia et al. (26) , it was reported that foetal tissues and neoplasm exhibit lower activities than the cognate adult tissues. Despite the fact that the urinary biopterin levels in thyroid patients were lower than the controls, in the present study, higher biopterin concentrations were observed in malignant thyroid disorders in comparison with the benign thyroid group. Similar to thyroid group, the mean biopterin concentrations in breast patients were lower than the controls. Moreover, the reduction in biopterin concentrations in patients with breast disorders was considerably more than the biopterins in thyroid disease. In patients with breast disorders, DHPR activity as a related parameter to biopterin pathway was close to the mean enzyme activity of controls while it was lower than the mean DHPR activity in thyroid patients. The reduced DHPR activity in breast tumors is believed to be related to the characteristics of the tumor.
It can be concluded that analysis of these mechanisms on the tissue level may be more explanatory, it may reveal more informative results. Moreover; further studies with different cancer types are needed to answer and explain some points in maintenance of the pathway.
